Literature DB >> 26759330

Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance.

Iqbal Sahibzada1, Deepak Batura2, Giles Hellawell1.   

Abstract

PURPOSE: To compare multiparametric magnetic resonance imaging (mpMRI) with transrectal ultrasound-guided prostate biopsy (TRUS-bx) for the diagnosis and monitoring of small-volume prostate cancer (PCa) in patients on active surveillance (AS).
METHODS: In a retrospective cross-sectional validation study, 100 patients on AS for PCa underwent a systematic 12-core TRUS-bx (the gold standard) as well as mpMRI, on either a 1.5 or 3 Tesla scanner (32 and 68 patients, respectively). Three pathologists reported biopsy histology separately. A single, experienced radiologist scored mpMRI scans using the PI-RADS system. We compared left- and right-sided PI-RADS scores of the peripheral zone with TRUS-bx results of the relevant prostate lobe. We then estimated the specificity and sensitivity of mpMRI in diagnosing low-grade low-risk PCa in our AS cohort.
RESULTS: The sensitivity of mpMRI was 37% (95% CI 28-47%) and specificity was 85% (CI 76-92%) for cancer. The negative predictive value was 51% (CI 44-60%), and the positive predictive value was 76% (CI 62-87%). The positive and negative likelihood ratios were 2.5 and 0.7, respectively.
CONCLUSION: Because of its low specificity and low negative predictive value, mpMRI is not suitable for diagnosing low-grade small-volume PCa. However, because of a specificity of 85% and a negative likelihood ratio of 0.7, mpMRI may be useful for follow-up of previously TRUS-bx diagnosed patients who are on AS.

Entities:  

Keywords:  Active surveillance; Biopsy; MRI; Prostate neoplasms; Sensitivity and specificity

Mesh:

Year:  2016        PMID: 26759330     DOI: 10.1007/s11255-016-1212-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  28 in total

Review 1.  Prostate cancer: multiparametric MR imaging for detection, localization, and staging.

Authors:  Caroline M A Hoeks; Jelle O Barentsz; Thomas Hambrock; Derya Yakar; Diederik M Somford; Stijn W T P J Heijmink; Tom W J Scheenen; Pieter C Vos; Henkjan Huisman; Inge M van Oort; J Alfred Witjes; Arend Heerschap; Jurgen J Fütterer
Journal:  Radiology       Date:  2011-10       Impact factor: 11.105

2.  Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.

Authors:  Fergus V Coakley; Irene Chen; Aliya Qayyum; Antonio C Westphalen; Peter R Carroll; Hedvig Hricak; Mei-Hsiu Chen; John Kurhanewicz
Journal:  BJU Int       Date:  2007-01       Impact factor: 5.588

3.  Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy.

Authors:  A V D'Amico; A Desjardin; A Chung; M H Chen; D Schultz; R Whittington; S B Malkowicz; A Wein; J E Tomaszewski; A A Renshaw; K Loughlin; J P Richie
Journal:  Cancer       Date:  1998-05-15       Impact factor: 6.860

Review 4.  Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer.

Authors:  Virendra Kumar; Naranamangalam R Jagannathan; Sanjay Thulkar; Rajeev Kumar
Journal:  Int J Urol       Date:  2012-03-21       Impact factor: 3.369

5.  D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.

Authors:  Ardeshir R Rastinehad; Angelo A Baccala; Paul H Chung; Juan M Proano; Jochen Kruecker; Sheng Xu; Julia K Locklin; Baris Turkbey; Joanna Shih; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Pingkun Yan; Samuel Kadoury; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

Review 6.  Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities--a radiologist's perspective.

Authors:  Tobias Penzkofer; Clare M Tempany-Afdhal
Journal:  NMR Biomed       Date:  2013-09-03       Impact factor: 4.044

Review 7.  Functional MR imaging of prostate cancer.

Authors:  Young Jun Choi; Jeong Kon Kim; Namkug Kim; Kyoung Won Kim; Eugene K Choi; Kyoung-Sik Cho
Journal:  Radiographics       Date:  2007 Jan-Feb       Impact factor: 5.333

8.  Emergency hospital admissions attributable to infective complications of prostate biopsy despite appropriate prophylaxis: need for additional infection prevention strategies?

Authors:  G Gopal Rao; Deepak Batura
Journal:  Int Urol Nephrol       Date:  2013-08-10       Impact factor: 2.370

9.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

Authors:  K K Hodge; J E McNeal; M K Terris; T A Stamey
Journal:  J Urol       Date:  1989-07       Impact factor: 7.450

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  7 in total

1.  Contrast-enhanced magnetic resonance imaging with a novel nano-size contrast agent for the clinical diagnosis of patients with lung cancer.

Authors:  Jianwei Gao; Lei Li; Xia Liu; Rui Guo; Bin Zhao
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

2.  Application of a novel targeting nanoparticle contrast agent combined with magnetic resonance imaging in the diagnosis of intraductal papillary mucinous neoplasm.

Authors:  Min Sun; Liqing Kang; Yanchao Cui; Guoce Li
Journal:  Exp Ther Med       Date:  2018-06-22       Impact factor: 2.447

3.  Combination of magnetic resonance imaging and targeted contrast agent for the diagnosis of myocardial infarction.

Authors:  Jiangjun Qin; Shuchang Zhou; Zhiwei Li; Yinan Chen; Qun Qin; Tao Ai
Journal:  Exp Ther Med       Date:  2018-08-13       Impact factor: 2.447

4.  Predicting side-specific prostate cancer extracapsular extension: a simple decision rule of PSA, biopsy, and MRI parameters.

Authors:  Piotr Zapała; Bartosz Dybowski; Ewa Bres-Niewada; Tomasz Lorenc; Agnieszka Powała; Zbigniew Lewandowski; Marek Gołębiowski; Piotr Radziszewski
Journal:  Int Urol Nephrol       Date:  2019-06-10       Impact factor: 2.370

5.  Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: Yes.

Authors:  Henk G van der Poel; Roderick C N van den Bergh
Journal:  Int Braz J Urol       Date:  2016 May-Jun       Impact factor: 1.541

6.  Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.

Authors:  Julie Y An; Abhinav Sidana; Peter L Choyke; Bradford J. Wood; Peter A Pinto; İsmail Barış Türkbey
Journal:  Balkan Med J       Date:  2017-09-29       Impact factor: 2.021

Review 7.  MRI findings guiding selection of active surveillance for prostate cancer: a review of emerging evidence.

Authors:  Zachary A Glaser; Kristin K Porter; John V Thomas; Jennifer B Gordetsky; Soroush Rais-Bahrami
Journal:  Transl Androl Urol       Date:  2018-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.